Drugs / RX-0201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02089334 | Aug 2014 → Apr 2018 | renal cell carcinoma | Rexahn Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01028495 | May 2009 → Jul 2012 | malignant pancreatic neoplasm | Rexahn Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RX-0201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02089334 ↗ |
| Route | Intravenous | “RX-0201 will be administered at 250 mg/m2/day in a 24-hour continuous intravenous infusion” NCT01028495 ↗ |